Increasing the bioavailability of simple dietary plant-derived COX-2 and NF-κB inhibitors, such as apigenin, might be of value in lupus therapy as well as for suppressing inflammation in other Th17-mediated inflammatory diseases like rheumatoid arthritis, Crohn disease, and psoriasis and in prevention of inflammation-based tumors overexpressing COX-2 (colon, breast). Here, NFKB1 is linked to systemic lupus erythematosus.